Clinical Trials
12 trialsNCT06770582 2026-06-11
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT07566156 2026-06-08
EV-309
Astellas Pharma Inc
Phase 3 Recruiting
NCT04658862 2026-06-05
SunRISe-2
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT07000084 2026-06-02
GAIN-BCG
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT03775265 2026-05-29
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04579224 2026-05-29
Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT06388720 2026-05-29
IMGeS
National Cancer Center, Korea
Phase 2 Recruiting
NCT03682068 2026-05-28
NILE
AstraZeneca
Phase 3 Active not recruiting
NCT03924856 2026-05-28
KEYNOTE-866
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT06225596 2026-05-27
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
BicycleTx Limited
Phase 2 Active not recruiting
NCT07608224 2026-05-27
HOPE-07-MIBC
West China Hospital
Phase 2/3 Not yet recruiting
NCT04216290 2026-05-22
A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting